Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

emtelligent turns unstructured data into coded clinical insights, powering payer and oncology workflows to improve trial screening, EHR-to-EDC transfer, and decisions. ViroMissile shares phase 1 ...

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...

Although the results from persevERA were not statistically significant, they may support using oral SERDs for patients with ER+/HER2– breast cancer. Data from the phase 3 SENOMAC trial showed that ...

Updated data from the ASC4FIRST trial affirm asciminib as the treatment of choice for many patients with chronic myeloid leukemia in chronic phase. Experts discuss abstracts from the 2026 ASCO Annual ...